Journal:

Article Title: Activation of the Lbc Rho Exchange Factor Proto-Oncogene by Truncation of an Extended C Terminus That Regulates Transformation and Targeting

doi:

Figure Lengend Snippet: Northern blot analysis of proto-lbc mRNA expression in human tissues (A) and human cancer cell lines HL-60 (promyelocytic leukemia), HeLa (cervical epitheloid carcinoma), K-562 (erythroleukemia), MOLT-4 (lymphoblastic leukemia), Raji (Burkitt’s lymphoma), SW480 (colorectal adenocarcinoma), A549 (lung carcinoma), and G361 (melanoma). (B) Northern blots were obtained from Clontech.

Article Snippet: These results indicate that lbc is expressed in myeloid and lymphoid lineages, a variety of epithelial tissues, and skeletal muscle. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG. 6 caption a7 Northern blot analysis of proto- lbc mRNA expression in human tissues (A) and human cancer cell lines HL-60 (promyelocytic leukemia), HeLa (cervical epitheloid carcinoma), K-562 (erythroleukemia), MOLT-4 (lymphoblastic leukemia), Raji (Burkitt’s lymphoma), SW480 (colorectal adenocarcinoma), A549 (lung carcinoma), and G361 (melanoma). (B) Northern blots were obtained from Clontech.

Techniques: Northern Blot, Expressing

Journal: EMBO Molecular Medicine

Article Title: A statin-regulated microRNA represses human c-Myc expression and function

doi: 10.1002/emmm.201101045

Figure Lengend Snippet: Reporter screening to identify miRNAs that repress c-Myc and target the 3′UTR of the MYC gene. Assay 1 identifies miRNAs that down-regulate the expression of luc , which is driven by the E2F2 promoter. The y -axis denotes the relative luminescence units (RLU) of luc normalized to that of Rluc from pRL-TK compared with that of the vector control. miR-33b down-regulates the expression of Rluc upstream of the 3′UTR of MYC driven by a constitutively active promoter in Assay 2. The y -axis denotes the RLU of Rluc normalized to that of luc from the pGL3-Promoter compared with that of the vector control. Mutating two E-boxes of the E2F2 promoter abolishes the regulation of luc expression by miR-33b in Assay 1. RLU of cells with both the parental vector and the mutant promoter construct (pE2F2Mut-luc) is used as a reference. Modulation of Rluc expression by miR-33b is abolished with a mutant MYC 3′UTR. On the left is a schematic representation of miR-33b complementary binding to MYC 3′UTRWT and 3′UTRMut in which the miR-33b binding site is compromised. Assay 2 (right) is performed with RLU of cells transfected with the parental vector plus 3′UTRWT or that with the parental vector plus 3′UTRMut as a reference. Immunoblotting analyses show that down-regulation of c-Myc by miR-33b is dose dependent and miR-203 does not reduce c-Myc protein levels. qRT-PCR shows that MYC mRNA levels are reduced when miR-33b is overexpressed. Schematic representation of the binding of miR-33b, a miR-33b mutant (miR-33bM), or miR-33a to the MYC 3′UTR. c-Myc and its transcriptional targets, cyclin E and ODC, are down-regulated by miR-33b, but not miR-33a or miR-33bM, while GADD45α is up-regulated. Numbers across the top of the blot indicate the relative levels of c-Myc normalized to β-actin.

Article Snippet: The following primary antibodies were used in Western blotting analyses: c-Myc (cat. no. sc-40), cyclin E (sc-25303), VEGF-A (sc-7269), ODC (sc-21516) and Gadd45 (sc-6850) obtained from Santa Cruz Biotechnology (Santa Cruz, CA), Abca1 (ab7360) from Abcam (Cambridge, MA); Pim1 (#3247), and Bcl2 (#2870) from Cell Signaling Technology (Beverly, MA), and β-actin (AC-15) from Sigma (St. Louis, MO).

Techniques: Gene Assay, Expressing, Plasmid Preparation, Control, Mutagenesis, Construct, Binding Assay, Transfection, Western Blot, Quantitative RT-PCR

Journal: EMBO Molecular Medicine

Article Title: A statin-regulated microRNA represses human c-Myc expression and function

doi: 10.1002/emmm.201101045

Figure Lengend Snippet: Protein levels of c-Myc and its transcriptional targets cyclin E and ODC are down-regulated by miR-33b. GADD45α, a c-Myc transrepressional target, is upregulated. miR-33b leads to increased G1 arrest. On the left is a representative image of a single run with the y -axis denoting events (the number of cells) and the x -axis denoting the emitted fluorescence of the DNA dye (PI); a bar graph on the right is provided to summarize the three independent runs. miR-33b decreases cell proliferation. miR-33b expression reduces cell proliferation in the presence of exogenously expressed c-Myc with a native but not with a mutant 3′UTR. miR-33b overexpression results in down-regulation of miR-9. miR-33b reduces cell migration. The upper panel is a representative image of migrated cells; the bottom panel is a bar graph summarizing three independent experiments. miR-33b decreases anchorage-independent colony formation.

Article Snippet: The following primary antibodies were used in Western blotting analyses: c-Myc (cat. no. sc-40), cyclin E (sc-25303), VEGF-A (sc-7269), ODC (sc-21516) and Gadd45 (sc-6850) obtained from Santa Cruz Biotechnology (Santa Cruz, CA), Abca1 (ab7360) from Abcam (Cambridge, MA); Pim1 (#3247), and Bcl2 (#2870) from Cell Signaling Technology (Beverly, MA), and β-actin (AC-15) from Sigma (St. Louis, MO).

Techniques: Fluorescence, Expressing, Mutagenesis, Over Expression, Migration

Journal: EMBO Molecular Medicine

Article Title: A statin-regulated microRNA represses human c-Myc expression and function

doi: 10.1002/emmm.201101045

Figure Lengend Snippet: A screening assay identified lovastatin as a compound that inhibits Daoy cell growth. Lovastatin treatment inhibits the growth of Daoy but not D283 cells. Lovastatin treatment increases the RNA levels of miR-33b and SREBF1 and reduces that of MYC in Daoy but not in D283 cells. Lovastatin results in down-regulation of c-Myc, cyclin E, and ODC and upregulation of Gadd45α in Daoy but not in D283 cells. Cell cycle analyses of Daoy (left) and D283 (right) cells treated with lovastatin, with the final concentration of lovastatin (0–10 µM) indicated on the x -axis. Lovastatin treatment activates the luciferase reporter driven by the SREBF1∼miR-33b promoter in Daoy and D283 cells. Mevalonate inhibits lovastatin-induced miR-33b and miR-33a expression. Mevalonate inhibits c-Myc down-regulation and SREBF1 upregulation induced by lovastatin in Daoy cells. miR-33b inhibition rescues c-Myc down-regulation by lovastatin treatment. NegControl, Negative Control #1; Anti-miR-33b, Anti-miR™ miR-33b inhibitors (Ambion). Left: c-Myc expression using Western blot (numbers indicating the relative c-Myc levels normalized to β-actin); Right: G1 cell cycle arrest analysis using flow cytometry.

Article Snippet: The following primary antibodies were used in Western blotting analyses: c-Myc (cat. no. sc-40), cyclin E (sc-25303), VEGF-A (sc-7269), ODC (sc-21516) and Gadd45 (sc-6850) obtained from Santa Cruz Biotechnology (Santa Cruz, CA), Abca1 (ab7360) from Abcam (Cambridge, MA); Pim1 (#3247), and Bcl2 (#2870) from Cell Signaling Technology (Beverly, MA), and β-actin (AC-15) from Sigma (St. Louis, MO).

Techniques: Screening Assay, Concentration Assay, Luciferase, Expressing, Inhibition, Negative Control, Western Blot, Flow Cytometry

Journal: International Journal of Molecular and Cellular Medicine

Article Title: Sesamin Acts as Anti-leukemic Compound Interacting with Novel Phosphoprotein Targets and Inducing Apoptosis in Leukemic Cells

doi: 10.22088/IJMCM.BUMS.11.1.1

Figure Lengend Snippet: Cytotoxic effects of sesamin on (a) MOLT-4 and (b) NB4 cell line after 24 hour and 48 hour treatments compare with PBMC cells after 48 hour treatment. The results showed the percentage of cell inhibition measured by MTT assay. IC 50 at 48 hours for MOLT-4 and NB4 were reported as 104.84 and 121.00 µg/mL, respectively. Data were expressed as the mean±SD of independently three experiments. The differences between sesamin treated and untreated were examined for the statistical significance: *, p < 0.05; **, p < 0.01; ***, p < 0.001

Article Snippet: Leukemic Cell culture Acute lymphoblastic leukemia (ALL) MOLT-4 and acute promyelocytic leukemia (AML) NB4 cells purchased from Cell Lines Service GmbH (Eppelheim, Germany) were cultured in 10% fetal bovine serum and 2% penicillin-streptomycin supplements in RPMI-1640 medium at the condition of 37 o C and 5% CO 2 .

Techniques: Inhibition, MTT Assay

Journal: International Journal of Molecular and Cellular Medicine

Article Title: Sesamin Acts as Anti-leukemic Compound Interacting with Novel Phosphoprotein Targets and Inducing Apoptosis in Leukemic Cells

doi: 10.22088/IJMCM.BUMS.11.1.1

Figure Lengend Snippet: The relative normalized expression of apoptotic genes in (a) MOLT-4 and (b) NB4 after sesamin treatment at IC 50 values of 100 and 120 µg/mL, respectively, for 48 hours. The experiment was determined by Real-time PCR. Data were expressed as the mean±SEM of three independent experiments. The differences between sesamin treated and untreated were examined for the statistical significance: *, p < 0.05; **, p < 0.01

Article Snippet: Leukemic Cell culture Acute lymphoblastic leukemia (ALL) MOLT-4 and acute promyelocytic leukemia (AML) NB4 cells purchased from Cell Lines Service GmbH (Eppelheim, Germany) were cultured in 10% fetal bovine serum and 2% penicillin-streptomycin supplements in RPMI-1640 medium at the condition of 37 o C and 5% CO 2 .

Techniques: Expressing, Real-time Polymerase Chain Reaction

Journal: International Journal of Molecular and Cellular Medicine

Article Title: Sesamin Acts as Anti-leukemic Compound Interacting with Novel Phosphoprotein Targets and Inducing Apoptosis in Leukemic Cells

doi: 10.22088/IJMCM.BUMS.11.1.1

Figure Lengend Snippet: Venn diagram shows a set of 14 phosphoproteins present only in sesamin treated MOLT-4 (blue) and a different set of 14 phosphoproteins present only in sesamin treated NB4 (yellow)

Article Snippet: Leukemic Cell culture Acute lymphoblastic leukemia (ALL) MOLT-4 and acute promyelocytic leukemia (AML) NB4 cells purchased from Cell Lines Service GmbH (Eppelheim, Germany) were cultured in 10% fetal bovine serum and 2% penicillin-streptomycin supplements in RPMI-1640 medium at the condition of 37 o C and 5% CO 2 .

Techniques:

Journal: International Journal of Molecular and Cellular Medicine

Article Title: Sesamin Acts as Anti-leukemic Compound Interacting with Novel Phosphoprotein Targets and Inducing Apoptosis in Leukemic Cells

doi: 10.22088/IJMCM.BUMS.11.1.1

Figure Lengend Snippet: Heatmap of phosphoproteins with significant difference in expression of (A) MOLT-4 and (B) NB4 treated with sesamin in various times compare with the control. The color indicates the expression level from low (green) to high (red). The blue arrow indicates the selected phosphoproteins

Article Snippet: Leukemic Cell culture Acute lymphoblastic leukemia (ALL) MOLT-4 and acute promyelocytic leukemia (AML) NB4 cells purchased from Cell Lines Service GmbH (Eppelheim, Germany) were cultured in 10% fetal bovine serum and 2% penicillin-streptomycin supplements in RPMI-1640 medium at the condition of 37 o C and 5% CO 2 .

Techniques: Expressing

Journal: International Journal of Molecular and Cellular Medicine

Article Title: Sesamin Acts as Anti-leukemic Compound Interacting with Novel Phosphoprotein Targets and Inducing Apoptosis in Leukemic Cells

doi: 10.22088/IJMCM.BUMS.11.1.1

Figure Lengend Snippet: The schematic diagram shows the interactions between sesamin, caspase-3 (CASP3), caspase-7 (CASP7), caspase-8 (CASP8), caspase-9 (CASP9), BCL-2, and selected phosphoprotein; PARP4 and IPPK, in MOLT-4 and NB4 leukemic cell lines using STITCH database. The round shape represents protein. The oval shape represents chemical. Red circle indicates selective proteins. Red dashed circle indicates selective chemicals

Article Snippet: Leukemic Cell culture Acute lymphoblastic leukemia (ALL) MOLT-4 and acute promyelocytic leukemia (AML) NB4 cells purchased from Cell Lines Service GmbH (Eppelheim, Germany) were cultured in 10% fetal bovine serum and 2% penicillin-streptomycin supplements in RPMI-1640 medium at the condition of 37 o C and 5% CO 2 .

Techniques:

Journal: Biomaterials Research

Article Title: Synthesizing efficacious genistein in conjugation with superparamagnetic Fe 3 O 4 decorated with bio-compatible carboxymethylated chitosan against acute leukemia lymphoma

doi: 10.1186/s40824-020-00187-2

Figure Lengend Snippet: The impact of 48 h treatment with different dose of Genistein on Apoptosis of JURKET cell line obtained by Flow Cytometry (The Flow Cytometry charts supply in )

Article Snippet: MOLT-4, MOLT17 and Jurket cell lines purchased from Pasteur Institute of Iran, centrifuged (130 g for 5 min) and suspended in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 100 mg/mL streptomycine, and 100 U/mL penicillin then cultured in 6-well micro plates (9.6 cm 2 ) with concentration of 15 × 10 4 cells/ml and incubated in a humidified incubator by standard cell culture conditions (37 °C and 5% CO 2 ).

Techniques: Flow Cytometry